Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the AI stocks that will go to the moon. On February 18, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) came under pressure after regulatory ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

There's currently a lot of noise surrounding Sony's PC strategy, and how the company is supposedly set to back away from its stance of releasing key first-party titles on PC as well as PS5. Over on ...

One Year After Green Bank’s Demise, Court Mulls Future of Grant-Based Climate Policy Nation’s First Critical Minerals Mine Nears Approval in Biodiversity Hotspot Summer in March? Unusual Heat Wave ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

If Americans during President Donald Trump’s first term were exhausted by his “controversy and chaos,” they now appear to be similarly distressed by his “backtracking and blowing things up,” according ...

Java Development Kit (JDK) 26, a planned update to standard Java due March 17, 2026, has reached its second release candidate (RC) stage. The RC is open for critical bug fixes, with the feature set ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...